Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

ChemoCentryx Inc. (CCXI)

48.87   -0.72 (-1.45%) 02-21 16:00
Open: 49.56 Pre. Close: 49.59
High: 49.63 Low: 48.07
Volume: 279,675 Market Cap: 2848M
ChemoCentryx Inc is a biopharmaceutical company. It is engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 49.651 - 49.985 49.985 - 50.262
Low: 47.435 - 47.758 47.758 - 48.025
Close: 48.393 - 48.922 48.922 - 49.36

Technical analysis

as of: 2020-02-21 4:28:34 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 59.99     One year: 70.07
Support: Support1: 43.07    Support2: 37.94
Resistance: Resistance1: 51.36    Resistance2: 59.99
Pivot: 47.81
Moving Average: MA(5): 49.16     MA(20): 46.09
MA(100): 26.31     MA(250): 16.40
MACD: MACD(12,26): 3.02     Signal(9): 3.19
Stochastic oscillator: %K(14,3): 84.98     %D(3): 87.27
RSI: RSI(14): 66.01
52-week: High: 51.36  Low: 6.16  Change(%): 348.3
Average Vol(K): 3-Month: 123844  10-Days: 46146

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
CCXI has closed below upper band by 37.2%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.

The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 58.27
Shares Float (M) 40.52
% Held by Insiders 30.55
% Held by Institutions 63.42
Shares Short (K) 2030
Shares Short P. Month (K)

Stock Financials

EPS -0.930
Book Value (p.s.) 1.060
PEG Ratio
Profit Margin -143.30
Operating Margin -151.29
Return on Assets (ttm) -16.6
Return on Equity (ttm) -121.8
Qtrly Rev. Growth 17.9
Gross Profit (p.s.) -0.341
Sales Per Share
EBITDA (p.s.) -0.910
Qtrly Earnings Growth
Operating Cash Flow (M) -65.20
Levered Free Cash Flow (M) -28.59

Stock Valuations

P/E -52.55
P/E Growth Ratio -0.01
P/BV 46.10
P/S 75.18
P/CF -43.68

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.